Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.

By C. Brightling, W. Monteiro, R. Ward, D. Parker, M. Morgan, A. Wardlaw, I. Pavord. The Lancet, 2000

626 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 (2019, background): “Short term clinical trials have shown that higher sputum eosinophil counts in stable COPD patients predict a greater lung function response to corticosteroids(6, 7).”
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations (2006, background): “The current authors selected 3%, rather than .2%, because it is likely that there is a gray area around the cut-off point of 2%. Differences between 2 and 3% are subtle and 3% seems to be more clinically relevant with respect to short-term benefit from the addition of inhaled steroid treatment [7, ”
Mediators of Chronic Obstructive Pulmonary Disease (2004, background): “The presence of eosinophils in patients with COPD predicts a response to corticosteroids and may indicate coexisting asthma (Brightling et al., 2000; Papi et al., 2000).”